New Antibiotic Target Could Mean the End of Pneumonia

Scientists have found a molecular Achilles heel in the organism that causes pneumonia, providing a target for the development of a new class of antibiotics that could eventually eradicate the disease.

Their report is scheduled to appear in the Dec. 28 edition of Biochemistry, a peer-reviewed journal of the American Chemical Society, the worlds largest scientific society.

Streptococcus pneumoniae places an enormous burden on the welfare of humanity, says Thomas Leyh, PhD, a professor of biochemistry at the Albert Einstein College of Medicine in New York and lead author of the paper. Worldwide, the organism takes the lives of some 3,700 people daily, the majority of whom are children below the age of five.

Decades of antibiotic use have produced drug-resistant strains of S. pneumoniae that are capable of evading even our so-called last-line-of-defense antibiotics, such as vancomycin. In the United States alone, the roughly 7 million annual cases of inner ear infections caused by this organism saddle the U.S. heathcare system with an estimated $5 billion burden, Leyh says.

The virulence of S. pneumoniae requires a properly functioning channel called the isoprenoid biosynthetic pathway. Leyh and his colleagues have discovered that an intermediate in the pathway diphosphomevalonate, or DPM can inhibit the first enzyme, effectively shutting down the whole process.

If you switch this pathway off, the organism is in big trouble, Leyh says. Without this channel, the normally pathogenic S. pneumoniae is unable to survive in mouse lungs and its virulence is severely attenuated.

Remarkably, the human enzyme is not influenced by the inhibitor, Leyh says. This means that S. pneumoniae in human lungs or blood should be inhibited without any negative effect on human metabolism.

DPM binds to its own pocket on the enzyme, and therefore cannot be dislodged by the enzymes natural substrates. Pharmaceutical companies consider such targets to be among the most important elements in deciding whether or not to pursue a problem, according to Leyh. We recognize the need to work with a pharmaceutical partner to bring our basic research discovery to the bedside, and, hopefully, to cure this disease.

The researchers plan to use DPM as a template for developing novel antibiotics to cure pneumonia and other streptococcal diseases, such as meningitis. We consider DPM a very powerful lead compound, Leyh continues. Its about as compelling as it can be at this stage. Leyhs lab is currently developing and testing five compounds based on the DPM template for their potential as new antibiotics.

Source: American Chemical Society